Literature DB >> 29354676

The COPD Pipeline XXXVI.

Nicholas Gross1.   

Abstract

Year:  2017        PMID： 29354676      PMCID： PMC5764845          DOI： 10.15326/jcopdf.4.4.2017.0164

Source DB:  PubMed          Journal:  Chronic Obstr Pulm Dis        ISSN： 2372-952X


× No keyword cloud information.
  3 in total

Review 1.  Inhaled colistin monotherapy for respiratory tract infections in adults without cystic fibrosis: a systematic review and meta-analysis.

Authors:  Konstantinos Z Vardakas; Georgios L Voulgaris; George Samonis; Matthew E Falagas
Journal:  Int J Antimicrob Agents       Date:  2017-06-29       Impact factor: 5.283

2.  SPX-101 Is a Novel Epithelial Sodium Channel-targeted Therapeutic for Cystic Fibrosis That Restores Mucus Transport.

Authors:  David W Scott; Matthew P Walker; Juliana Sesma; Bryant Wu; Timothy J Stuhlmiller; Juan R Sabater; William M Abraham; Timothy M Crowder; Dale J Christensen; Robert Tarran
Journal:  Am J Respir Crit Care Med       Date:  2017-09-15       Impact factor: 21.405

3.  The anti-CD14 antibody IC14 suppresses ex vivo endotoxin stimulated tumor necrosis factor-alpha in patients with chronic heart failure.

Authors:  Sabine Genth-Zotz; Stephan von Haehling; Aidan P Bolger; Paul R Kalra; Roland Wensel; Andrew J S Coats; Hans-Dieter Volk; Stefan D Anker
Journal:  Eur J Heart Fail       Date:  2005-12-05       Impact factor: 15.534
  3 in total
  1 in total

1.  A Physiologically Based Pharmacokinetic Model to Predict Potential Drug-Drug Interactions and Inform Dosing of Acumapimod, an Oral p38 MAPK Inhibitor.

Authors:  Alex Agyemang; Colm Farrell; William Moore; Jacqueline Parkin
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2020-12-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.